Hidradenitis Suppurativa News

New pooled results from the BE HEARD phase 3 trials show bimekizumab reduces disease severity in patients with moderate to severe hidradenitis suppurativa, according to a UCB press release.

NEW YORK — Hidradenitis suppurativa disproportionally affects patients with skin of color, resulting in many management and quality of life disparities, according to a speaker at the Skin of Color Update 2023 Meeting.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.

Patients in sexual and gender minorities who have chronic inflammatory skin diseases often experience financial and non-financial barriers to care, according to a study.

Hormonal treatments for hidradenitis suppurativa — particularly finasteride, spironolactone and metformin — are efficacious and safe for women, but dermatologists should be aware of treatment interactions, according to a review.

Genetic variants located near KLF5 and SOX9 may be associated with a higher risk for hidradenitis suppurativa, according to a study.

Researchers have dosed the first patient in Step-Up HS, a phase 3 study evaluating Rinvoq for moderate to severe hidradenitis suppurativa in adults and adolescents, AbbVie announced in a press release.

Women of childbearing age with hidradenitis suppurativa are often prescribed teratogenic medications, and the majority do not receive physician-led counsel on how these medications could impact childbearing, according to published data.

The European Medicines Agency has accepted for review the marketing authorization application for bimekizumab for moderate to severe hidradenitis suppurativa treatment in adults, UCB announced in a press release.